Search hospitals > Georgia > Augusta
Southeast Retina Center
Claim this profileAugusta, Georgia 30909
Global Leader in Age-Related Macular Degeneration
Global Leader in Macular Degeneration
Conducts research for Diabetic Macular Edema
Conducts research for Diabetic Retinopathy
Conducts research for Retinal Disease
102 reported clinical trials
2 medical researchers
Summary
Southeast Retina Center is a medical facility located in Augusta, Georgia. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Disease and other specialties. Southeast Retina Center is involved with conducting 102 clinical trials across 37 conditions. There are 2 research doctors associated with this hospital, such as Dennis M. Marcus, MD and Augusta Site PI.Area of expertise
1Age-Related Macular Degeneration
Global LeaderStage I
CFI positive
Stage II
2Macular Degeneration
Global LeaderStage I
Stage II
CFI positive
Top PIs
Dennis M. Marcus, MDSoutheast Retina Center, P.C.3 years of reported clinical research
Studies Diabetic Retinopathy
Studies Diabetic Macular Edema
3 reported clinical trials
5 drugs studied
Augusta Site PIAugusta Location5 years of reported clinical research
Studies Diabetic Retinopathy
Studies Diabetic Macular Edema
1 reported clinical trial
1 drug studied
Clinical Trials running at Southeast Retina Center
Age-Related Macular Degeneration
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Macular Pucker
Choroidal Neovascularization
Choroidal neovascularization
Retinal Degeneration
Retinal Disease
None
4D-150 + EYLEA
for Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Recruiting2 awards Phase 34 criteria
PDS Implant with Ranibizumab
for Age-Related Macular Degeneration
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Recruiting2 awards Phase 33 criteria
Avacincaptad Pegol
for Macular Degeneration
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision. Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy. This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor has decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas). People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for up to 3 years or up to 5 years, depending on when they start the study.
Recruiting1 award N/A3 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Southeast Retina Center?
Southeast Retina Center is a medical facility located in Augusta, Georgia. This center is recognized for care of Age-Related Macular Degeneration, Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Disease and other specialties. Southeast Retina Center is involved with conducting 102 clinical trials across 37 conditions. There are 2 research doctors associated with this hospital, such as Dennis M. Marcus, MD and Augusta Site PI.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.